Article
A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
The oncologist - 1 May 2014
Vasan Neil, Yelensky Roman, Wang Kai, Moulder Stacy, Dzimitrowicz Hannah, Avritscher Rony, Wang Baliang, Wu Yun, Cronin Maureen T, Palmer Gary, Symmans W Fraser, Miller Vincent A, Stephens Philip, Pusztai Lajos
Abstract excerpt
The aim of this study was to assess the frequency of potentially actionable genomic alterations in breast cancer that could be targeted with approved agents or investigational drugs in clinical trials using a next-generation sequencing-based genomic profiling assay performed in a Clinical Laboratory Improvement Amendments-certified and College of American Pathologists-accredited commercial laboratory. Methods....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.